Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOACs vs ASA for stroke prevention in AF and previous ICH
NCT02998905Phase 2Completed
- Sponsor
- Population Health Research Institute
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in stroke, sponsored by Population Health Research Institute. Started Apr 2017; status: completed.
02
Drugs
rivaroxaban
03
Conditions
stroke
Beyond the preview
Go deeper on NCT02998905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998905.